SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Pulmonary, Allergy and Critical Care Medicine



[Return To Index page]
photo Joseph M. Pilewski, MD

Associate Chief, Division of Pulmonary, Allergy & Critical Care Medicine

Associate Professor of Medicine, Cell Biology, Physiology & Pediatrics

Email: pilewskijm@upmc.edu

Phone: 412-647-8477

Contact
Office: UPMC Montefiore Hospital, NW628
3459 Fifth Avenue
Pittsburgh, PA 15213
 
Phone: 412-647-8477
Fax: 412-692-2260
E-mail: pilewskijm@upmc.edu
Administrative Assistant:
M. Sharon Droppa
Email: droppam2@upmc.edu
Phone: 412-647-8477
Fax: 412-692-2260
Education and Training
Education
BA, Philosophy, College of the Holy Cross, 1983
MD, University of Rochester, 1987
Training
Medical Internship, Hospital of the University of Pennsylvania, 1988
Medical Residency, Hospital of the University of Pennsylvania, 1990
Pulmonary & Critical Care Fellowship, Hospital of the University of Pennsylvania, 1991
Research Fellowship, University of Pennsylvania - Pulmonary Division, 1994
Research Interest
Dr. Pilewski’s research interests mirror his clinical interest and expertise. He directs a research program in epithelial cell biology focused on ion transport and mucin structure and function in normal and Cystic Fibrosis airways, and leads translational research projects focused on development of new therapies for CF and other diseases of mucus obstruction, and identification of biomarkers of disease activity. He is a co-investigator on NIH and CF Foundation sponsored center grants focused on CF, and a co-investigator in the Cystic Fibrosis Foundation Therapeutics Development Network.
Clinical Interest
Dr. Pilewski has a longstanding interest in Cystic Fibrosis and other diseases causing bronchiectasis and bronchiolitis. He is Co-director of the Adult Cystic Fibrosis program at the Antonio J and Janet Palumbo CF Center at Children’s Hospital of Pittsburgh of UPMC, and the University of Pittsburgh Medical Center. Dr. Pilewski’s other focus is lung transplantation, with special interest in patients with suppurative lung diseases like CF. He has been Medical Director of the Lung Transplant Program at the University of Pittsburgh Medical Center since 2004.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Locke, LW, Myerburg, MM, Weiner, DJ, Markovetz, MR, Parker, RS, Muthukrishnan, A, Weber, L, Czachowski, MR, Lacy, RT, Pilewski, JM, Corcoran, TE. Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung. Eur Respir J. 2016; May;47(5): 1392-401.
Morrell, MR, Pilewski, JM. Lung Transplantation for Cystic Fibrosis. Clin Chest Med. 2016; Mar;37(1): 127-38.
Crespo, MM, Bermudez, CA, Dew, MA, Johnson, BA, George, MP, Bhama, J, Morrell, M, D'Cunha, J, Shigemura, N, Richards, TJ, Pilewski, JM. Lung Transplantation in Patients with Scleroderma Compared with Pulmonary Fibrosis: Short and Long-term Outcomes in a Single Institution. Ann Am Thorac Soc. 2015; Dec 15.
Heidrich, E, Carattino, MD, Hughey, RP, Pilewski, JM, Kleyman, TR, Myerburg, MM. Intracellular Na+ regulates epithelial Na+ channel maturation. J Biol Chem. 2015; May 1;290(18): 11569-77.
Taylor-Cousar, J, Niknian, M, Gilmartin, G, Pilewski, JM, for the VX11-770-901 investigators. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States. J Cyst Fibros. 2015; Feb 11: S1569-1993.
Bermudez, CA, Shiose, A, Esper, SA, Shigemura, N, D'Cunha, J, Bhama, JK, Richards, TJ, Arlia, P, Crespo, MM, Pilewski, JM. Outcomes of intraoperative venoarterial extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation. Ann Thorac Surg. 2014; Dec; 98(6): 1936-42.
Markovetz, MR, Corcoran, TE, Locke, LW, Myerburg, MM, Pilewski, JM, Parker, RS. A Physiologically-Motivated Compartment-Based Model of the Effect of Inhaled Hypertonic Saline on Mucociliary Clearance and Liquid Transport in Cystic Fibrosis. PLoS One. 2014; Nov 19;9(11): e111972.
Zemke, AC, Shiva, S, Burns, JL, Moskowitz, SM, Pilewski, JM, Gladwin, MT, Bomberger, JM. Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cells. Free Radic Biol Med. 2014; Sep 16: S0891-5859(14)00402-X.
Locke, LW, Myerburg, MM, Markovetz, MR, Parker, RS, Weber, L, Czachowski, MR, Harding, TJ, Brown, SL, Nero, JA, Pilewski, JM, Corcoran, TE. Quantitative Imaging of Airway Liquid Absorption in Cystic Fibrosis. Eur Resp J. 2014; Apr 17.
Corcoran, TE, Thomas, KM, Garoff, S, Tilton, RD, Przybycien, TM, Pilewski, JM. Imaging the post deposition dispersion of an inhaled surfactant aerosol. J Aerosol Medicine Pulm Drug Del. 2012; Mar 6.
Sponsored Research/Activities
Title: The VX13-661-103 Standardized Protocol for Mucociliary Clearance (MCC) Data Processing Plan
Role: Principal Investigator
Funding Agency: Vertex
Start Year: 2015
End Year: 2016
Title: Development of an Embedded Palliative Care Program
Role: Principal Investigator
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2014
End Year: 2017
Title: A Healthy Literacy Sensitive Decision Aid about Transplantation for COPD Patients
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R21 HL121744
Start Year: 2014
End Year: 2016
Title: Translating CFTR Modulation from Animal Models to Human Samples
Role: Principal Investigator
Funding Agency: Cincinnati Childrens Hospital/Cystic Fibrosis Foundation
Start Year: 2012
End Year: 2013
Title: TDN Committee Chair
Role: Principal Investigator
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2011
End Year: 2016
Title: Lung Transplant Consortium
Role: Co-Principal Investigator
Funding Agency: Cystic Fibrosis Foundation Therapeutics, Inc.
Grant Number: RES
Start Year: 2017
End Year: 2019
Title: Translational Therapeutic Development Center
Role: Co-Principal Investigator
Funding Agency: Cystic Fibrosis Foundation
Grant Number: RES
Start Year: 2017
End Year: 2017
Title: Cadaveric Donor Lung and Bone Marrow Transplantation in Immunodeficiency Diseases
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI125050
Start Year: 2016
End Year: 2021
Title: Building Multilevel Models of Therapeutic Response in the Lungs
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: U01 HL131046
Start Year: 2016
End Year: 2020
Title: Generation of Novel Human Monoclonals for Lung Disease
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: R21 AI121815
Start Year: 2016
End Year: 2018
Title: Genome-Wide Analyses of Epigenetic Landscape of CF Airways
Role: Co-Investigator
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2016
End Year: 2018
Title: Transcriptomic Responses to Kalydeco - Role in Predicting Outcomes
Role: Co-Investigator
Funding Agency: Cystic Fibrosis Foundation Therapeutics, Inc.
Start Year: 2016
End Year: 2017
Title: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: U01 HL128954
Start Year: 2015
End Year: 2020
Title: Regulation of Alveolar Homeostasis in Acute Lung Injury
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL113655
Start Year: 2014
End Year: 2017
Title: Assessing Xenon CT Imaging Biomarkers in Lung Transplant Recipients
Role: Co-Investigator
Funding Agency: National Institute of Biomedical Imaging and Bioengineering
Grant Number: R21 EB017851
Start Year: 2014
End Year: 2016
Title: A Randomized Crossover Mucociliary Clearance Study of Aerosolized 7% NaCI Solution Administered Overnight by the tPAD Device to Subjects with Cystic Fibrosis
Role: Co-Investigator
Funding Agency: Parion Sciences, Inc./National Heart, Lung, & Blood Institute
Grant Number: R44 HL110502
Start Year: 2014
End Year: 2015
Title: BET Inhibitors and Cystic Fibrosis
Role: Co-Investigator
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2014
End Year: 2015
Title: BET Inhibitors and Cystic Fibrosis
Role: Co-Investigator
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2013
End Year: 2014
Title: Imaging Airway Liquid Absorption in Cystic Fibrosis
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL108929
Start Year: 2011
End Year: 2017
Title: Improving Inhaled Drug Delivery with Self-Dispersing Surfactant Films
Role: Co-Investigator
Funding Agency: Carnegie-Mellon University/National Heart, Lung, & Blood Institute
Grant Number: R01 HL105470
Start Year: 2011
End Year: 2016
Title: Therapeutic Development Center
Role: Co-Investigator
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2009
End Year: 2016
Title: Human Airway Cell and Tissue - Core A
Role: Core Director
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2015
End Year: 2019
Title: Basic and Translational Studies of Cystic Fibrosis - Core B
Role: Core Director
Funding Agency: National Institute of Diabetes, Digestive, & Kidney Disease
Grant Number: P30 DK072506
Start Year: 2015
End Year: 2018
Title: Basic and Translational Studies of Cystic Fibrosis (Core A)
Role: Core Director
Funding Agency: National Institute of Diabetes, Digestive, & Kidney Disease
Grant Number: P30 DK072506
Start Year: 2015
End Year: 2018
Title: Clinical Studies - Core B
Role: Core Director
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2015
End Year: 2017
Title: Human Airway and Tissue Core - Core A
Role: Core Director
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2011
End Year: 2015
Title: Clinical Studies Core - Core C
Role: Core Director
Funding Agency: Cystic Fibrosis Foundation
Start Year: 2011
End Year: 2015
Title: Basic and Clinical Studies of Cystic Fibrosis - Core B
Role: Core Director
Funding Agency: National Institute of Diabetes, Digestive, & Kidney Disease
Grant Number: P30 DK072506
Start Year: 2010
End Year: 2015
Title: Lung Epithelial-Immune Interactions in Respiratory Virus Infection
Role: Director
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL122307
Start Year: 2015
End Year: 2019
Notable Achievements
Harry Shwachman Clinical Investigator Award, Cystic Fibrosis Foundation, 1995-1998
Best Doctors in America, Northeast Edition, 1996
Best Doctors in America, 1999-2016
Breath of Life Award, Western Pennsylvania Chapter of Cystic Fibrosis Foundation, 2002
UPMC Award for Commitment and Excellence in Service (ACES), 2013